WGWenxian Guan

Wenxian Guan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wenxian Guan has a total of 145 co-authors. Here are the top co-authors by number of shared publications:

  • Xingzhou Wang

    Division of Gastric Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

    14 shared publications
  • Xiaofei Shen

    Division of Gastric Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

    11 shared publications
  • Xiaofeng Lu

    Division of Gastric Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

    11 shared publications
  • Xuefeng Xia

    Department of General Surgery, Drum Tower Clinical Medical College of Nanjing Medical University, Nanjing, P. R. China

    9 shared publications
  • En Xu

    Department of General Surgery, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China

    8 shared publications
  • Shangce Du

    Department of General Surgery, Drum Tower Clinical Medical College of Nanjing Medical University, Nanjing, P. R. China

    8 shared publications

Latest Publications

  • Open Access

    Recurrence‑related factors after discontinuation of adjuvant imatinib in intermediate‑ and high‑risk GIST: a retrospective cohort study

    by Yibo Huang, Xiaolong Zheng, Lin Gao, Lianlian Cao, Zhaoping Li, Hao Chen, Li Chen, Liang Tao, Meng Wang, Tingting Tao, et al.

  • Open Access

    Effect of lymph node dissection numbers after conversion immunochemotherapy on the survival of gastric cancer patients: a multi-center retrospective study

    by Mengjie Liang, Long Qian, Zhengyang Yang, Yiwen Sun, Shichao Ai, Peng Song, Qianyu Wang, Feng Sun, Xingzhou Wang, Xiaofeng Lu, et al.

    Objective: To investigate the influence of lymph node dissection on the prognosis of unresectable locally advanced gastric cancer (LAGC) after conversion immunochemotherapy (CICT). Methods: A total of 287 patients, including 227 from Nanjing Drum Tower Hospital and an external validation cohort of 60 patients (15 from Peking Union Medical College Hospital, 20 from Beijing Friendship Hospital, and 25 from PLA General Hospital) with pathologically diagnosed unresectable primary LAGC (cT3~4N+) underwent radical gastrectomy after multidisciplinary evaluation conversion immunochemotherapy (CICT) were enrolled, and their clinical data were collected. According to the pathological data of patients’ baseline data set, a clinical prediction model of patients’ overall survival (OS) and progression-free survival (PFS) was established, and based on COX regression model, the critical value of the number of lymph node dissection was determined by restricted cubic spline (RCS) analysis. Results: Univariate and multivariate COX regression analysis showed that lymph node metastasis (ypN+) was an independent risk factor for OS (P = 0.030) and PFS (P = 0.002). According to the results of COX regression analysis, the prediction model was established. RCS curve showed that the critical number of lymph node dissection was 21 and 28. Patients with 21–28 lymph node dissection had the best OS and PFS. Compared with the patients with 21–28 lymph nodes dissection, the patients with less than 21 lymph nodes dissection had worse OS (P<0.001) and PFS (P = 0.002). Those with more than 28 lymph nodes isolated had worse OS(P = 0.043) and PFS (P = 0.027). The PFS of patients with more than 28 lymph nodes dissection was better than the patients with less than 21lymph nodes dissection (P = 0.031). Although the difference was not statistically significant, the total OS of patients with more than 28 lymph nodes dissection was still higher than that of patients with less than 21 lymph nodes dissection (P = 0.077). Conclusion: Among patients after CICT, lymph node metastasis (ypN+) is an independent risk factor for the prognosis of patients. The survival benefit of patients with less than 21 lymph node dissection is significantly reduced, while those with more than 28 lymph node dissection are less than 21–28 lymph node dissection.

  • Open Access

    Aging modulation of the immune system and immunotherapy efficacy in cancer

    by Yurong Wang, Mengjie Liang, Yichen Mao, Wei Zhu, Xiaofei Shen, Wenxian Guan

    Immunosenescence is characterized by immune decline and chronic inflammation. With advancing age, the incidence of tumors increases significantly. Understanding how immunosenescence influences the initiation and progression of tumors, as well as its implications for tumor immunotherapy, has become a matter of urgent importance. This review begins with an analysis of the phenotypic changes and underlying mechanisms associated with immune system and immune cell aging, and further explores the interplay between immunosenescence and tumorigenesis. Evidence indicates that cytokines, cell interactions and other mediators serve as critical links connecting aging and cancer, exerting complex anti-tumor and pro-tumor effects. However, in the context of immunosenescence, these factors collectively contribute to the formation of an immunosuppressive tumor microenvironment (TME) that facilitates tumor immune evasion and proliferation. Clinical data reveal that immunotherapy in older adults is often challenged by variable treatment efficacy and reduced tolerance. This review systematically summarizes the data related to elderly patients in immunotherapy for different types of cancers, and discusses potential immunotherapy sensitization strategies tailored for elderly patients and the mechanisms and immunomodulatory effects of senescence-modulating drugs, with the aim of enhancing therapeutic response rates and improving safety profiles.


  • Open Access

    Correction to: NADPH oxidase 4 regulates anoikis resistance of gastric cancer cells through the generation of reactive oxygen species and the induction of EGFR

    by Shangce Du, Ji Miao, Zhouting Zhu, En Xu, Linsen Shi, Shichao Ai, Feng Wang, Xing Kang, Hong Chen, Xiaofeng Lu, et al.


  • Open Access

    A Multi-marker model based on serum IL-10 predicts response to conversion immunochemotherapy in gastric cancer patients: a retrospective cohort study

    by Xingzhou Wang, Hang Jiang, Mengjie Liang, Daming Cai, Shichao Ai, Qiongyuan Hu, Feng Wang, Feng Sun, Xuefeng Xia, Peng Song, et al.

    Conversion immunochemotherapy may enable curative surgery in patients with initially unresectable locally advanced gastric cancer, but its response rate remains low. Little evidence has shown how to easily predict therapeutic efficacy from hematological biomarkers, apart from tissue biomarkers. This study aimed to identify predictive factors for treatment response from hematological biomarkers and propose strategies for non-responsive patients. Clinical and laboratory data from 153 PD-L1 negative and microsatellite stable advanced gastric cancer patients treated with conversion immunochemotherapy followed by radical gastrectomy were retrospectively analyzed. Correlations between key indicators and treatment outcomes were assessed, and a nomogram was developed to predict tumor regression grade (TRG). TRG was strongly associated with the prognosis of advanced gastric cancer treated with conversion immunochemotherapy. Factors significantly related to TRG included hypertension, pre-treatment serum albumin levels, tumor size, post-treatment serum IL-10, IFN-γ, TNF-α, and changes in tumor-associated carbohydrate antigens before and after treatment. Hypertension, pre-treatment serum albumin levels, post-treatment IL-10 levels, and restoration in tumor-associated carbohydrate antigens were identified as independent predictors of TRG. Dynamic monitoring of serum albumin, IL-10, and tumor-associated carbohydrate antigens can help assess treatment response and identify patients sensitive to conversion immunochemotherapy. For non-responsive patients, strategies such as the associations observed require validation in prospective interventional trials before specific interventions can be recommended.


  • Open Access

    Inflammatory and nutritional markers predict response and prognosis of patients with locally advanced gastric cancer receiving neoadjuvant immunochemotherapy

    by Yiwen Sun, Mengjie Liang, Xingzhou Wang, Wenting Dong, ZhenShui Wu, Feng Sun, Xiaofeng Lu, Feng Wang, Song Liu, Meng Wang, et al.

    Metabolism plays an important role in the occurrence and development of gastric cancer, including in neoadjuvant immunochemotherapy. However, whether nutrition-related indicators can predict the efficacy of neoadjuvant immunochemotherapy and the prognosis of gastric cancer patients has not been addressed. This study systematically screens various nutritional indicators to explore their efficacy in predicting responses to neoadjuvant immunochemotherapy and patients’ prognosis in locally advanced gastric cancer (LAGC). We retrospectively analyzed 134 LAGC patients who underwent radical resection after neoadjuvant immunochemotherapy. According to postoperative tumor regression grade (TRG), these patients were divided into good responder group (TRG1-0) and poor responder group (TRG3-2) (AJCC/CAP guidelines). Inflammatory and/or nutritional markers were compared for their efficacy on predicting patients’ pathological tumor regression response. The univariate and multivariate logistic regression were carried out to identify the independent factors for predicting pathological tumor regression response, and a predictive nomogram model was further established. Among the total 134 LAGC patients, tumor specimens from 71 and 63 patients had TRG1-0 and TRG3-2 tumor responses, respectively. Multivariate analysis showed that controlling nutritional status (CONUT) score and nutrition risk screening 2002 (NRS2002) score were independent predictors of pathological tumor regression response (OR, 0.68; 95% CI, 0.50–0.91; P = 0.010 and OR, 0.66; 95% CI, 0.45–0.96; P = 0.031, respectively). With the use of ROC curve analysis, the optimal critical level of CONUT score and NRS2002 score were both 3. The CONUT-NRS2002 combined score was constructed. Patients with lower CONUT-NRS2002 had a better pathological response than those with higher CONUT-NRS2002 (P = 0.003). Moreover, Patients with higher CONUT-NRS2002 scores had poorer prognosis (P < 0.05). The nomogram based on CONUT score and NRS2002 score demonstrated good predictive ability and clinical application value. CONUT score and NRS2002 score are independent factors of pathological tumor regression response in LAGC patients after neoadjuvant immunochemotherapy. The constructed CONUT-NRS2002 combined score has a good potential in predicting pathological tumor regression response and prognosis of LAGC patients after neoadjuvant immunochemotherapy, serving as a new predictive indicator.


  • Open Access

    Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellular carcinoma through modulating METTL9-SLC7A11 axis

    by Junren Lu, Daming Cai, Long Qian, Yurong Wang, Shichao Ai, Peng Song, Feng Sun, Yiwen Sun, Mengjie Liang, Hang Jiang, et al.

    Sorafenib is the main treatment for advanced hepatocellular carcinoma (HCC), but drug resistance limits its effectiveness. Evidence increasingly indicates that, in addition to targeting tyrosine kinases, sorafenib also induces ferroptosis. However, current studies have not fully clarified the relationship between ferroptosis and sorafenib treatment sensitivity. Our bioinformatics analysis identified that SIX Homeobox 2 (SIX2), known for maintaining cellular stemness via the Wnt signaling pathway, was significantly upregulated in sorafenib-resistant tissues. Overexpression and knockdown experiments revealed that altering SIX2 expression affected HCC cell sensitivity to sorafenib and involved the ferroptosis pathway, suggesting a regulatory role for SIX2 in ferroptosis. RNA sequencing and CUT&Tag analysis showed that SIX2 directly regulated methyltransferase 9 (METTL9) expression. Co-immunoprecipitation (Co-IP) assays confirmed that METTL9 bound to SLC7A11, enhancing its stability and reducing degradation, thus regulating ferroptosis. Importantly, the role of SIX2 in ferroptosis operated independently of the classical glutathione peroxidase 4 (GPX4) pathway. In vitro studies further supported these findings, demonstrating that SIX2 knockdown increased sorafenib-induced ferroptosis in HCC, while METTL9 overexpression largely counteracted the effects of SIX2 knockdown. In mouse models, overexpression of SIX2 increased tumor resistance to sorafenib. Our findings suggest that modulating the ferroptosis pathway through SIX2 could enhance sorafenib sensitivity. This study provides the first evidence that SIX2 influences ferroptosis via the METTL9-SLC7A11 axis, thereby sensitizing HCC cells to sorafenib. Reducing SIX2 expression could thus represent a promising strategy to improve the efficacy of sorafenib in advanced HCC.


  • Open Access

    Expression Patterns of Immune Checkpoint Molecules and Their Clinical Values in Gastric Neuroendocrine Neoplasms

    by Mengjie Liang, Junren Lu, Xingzhou Wang, Peng Song, Shichao Ai, Daming Cai, Feng Sun, Xiaofeng Lu, Meng Wang, Shuang Fu, et al.

    INTRODUCTION: Gastric neuroendocrine neoplasms (g-NENs) are a rare type of stomach tumor. However, limited data exist about the expression and clinical significance of B7 family ligands/receptors in patients with g-NENs. Thus, we conducted this study to address this issue in a cohort of 112 patients with g-NENs. METHODS: Using immunohistochemistry, we mapped and quantified the expression of the B7 family ligands/receptors in 112 g-NEN samples: programmed cell death ligand 1 and 2 (PD-L1 and PD-L2), B7-H3, B7-H4, recombinant human galectin-9 (LGALS9), and CD155. Associations between the marker levels, clinicopathological variables, and survival were evaluated. RESULTS: The percentages of high expression of PD-L1, PD-L2, B7-H3, B7-H4, LGALS9, and CD155 in the cohort of 112 g-NEN cases were 37.5%, 55.4%, 46.4%, 37.5%, 46.4%, and 51.8%, respectively. Elevated expression of PD-L1, PD-L2, B7-H3, B7-H4, LGALS9, and CD155 was significantly associated with several clinicopathological characteristics. K-M analysis indicated that high expression levels of CD155, B7-H3, PD-L2, and LGALS9 were correlated with poor overall survival (OS) (P < 0.0001, P = 0.0002, P = 0.0319 and P = 0.0120, respectively). Multivariate Cox regression analysis indicated that high CD155 expression, vasculature invasion, and worse World Health Organization pathological grade were independent prognostic factors for OS (P = 0.007, P = 0.030, and P = 0.019, respectively). DISCUSSION: We detected variable expression of the PD-L1, PD-L2, B7-H3, B7-H4, LGALS9, and CD155 proteins in g-NENs. These results suggest that the expression level of CD155 may be a vital indicator of OS in patients with g-NENs. B7 family ligands/receptors could be potential immunotherapeutic targets for g-NENs.


  • Open Access

    Analysis of risk factors for liver metastasis in patients with gastric cancer and construction of prediction model: A multicenter study

    by Heng Yu, Hang Jiang, Xiaofeng Lu, Chunhua Bai, Peng Song, Feng Sun, Shichao Ai, Yi Yin, Qiongyuan Hu, Song Liu, et al.

    Background To retrospectively analyze the risk factors of liver metastases in patients with gastric cancer in a single center, and to establish a Nomogram prediction model to predict the occurrence of liver metastases. Methods A total of 96 patients with gastric cancer who were also diagnosed with liver metastasis (GCLM) and treated in our center from January 1, 2010 to December 31, 2020 were included. The clinical data of 1095 patients with gastric cancer who were diagnosed without liver metastases (GC) in our hospital from January 1, 2014 to December 31, 2017 were retrospectively compared by univariate and multivariate logistic regression. 309 patients diagnosed with gastric cancer in another medical center from January 1, 2014 to December 31, 2018 were introduced as external validation cohorts. Results Based on the training cohort, multivariate analysis revealed that tumor site (OR = 0.55, P = 0.046), N stage (OR = 4.95, P = 0.004), gender (OR = 0.04, P = 0.001), OPNI (OR = 0.95, P = 0.041), CEA (OR = 1.01, P = 0.018), CA724 (OR = 1.01, P = 0.006), CA242 (OR = 1.01, P = 0.006), WBC (OR = 1.13, P = 0.024), Hb (OR = 0.98, P < 0.001) were independent risk factors for liver metastasis in patients with gastric cancer, and Nomogram was established based on this analysis (C-statistics = 0.911, 95%CI 0.880–0.958), and the C-statistics of the external validation cohorts achieved 0.926. ROC analysis and decision curve analysis (DCA) revealed that the nomogram provided superior diagnostic value than single variety. Conclusions By innovatively introducing a new tumor location classification method, systemic inflammatory response indicators such as NLR and PLR, and nutritional index OPNI, the risk factors of gastric cancer liver metastasis were determined and a predictive Nomogram model was established, which can provide clinical prediction for patients with gastric cancer liver metastasis.


  • Open Access

    CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma

    by Yuyan Chen, Zhengyi Zhu, Xingyu Wu, Hui Li, Wenxian Guan, Haozhen Ren

    Currently, there is still a lack of novel and effective drug targets to improve the prognosis of hepatocellular carcinoma (HCC). Additionally, the role of CHEK2 in HCC has not been reported yet. The eQTLgen database and two HCC Genome-Wide Association Study (GWAS) datasets (ieu-b-4953, ICD10 C22.0) were used to find the drug target: CHEK2. Next, Colony, Edu, β-gal, and cell cycle analysis were facilitated to evaluate the role of CHEK2 knockout in HCC. In addition, Nultin-3 was added to evaluate the apoptosis of TP53-mutated HCC cells with CHEK2 knockout. Furthermore, MitoSox, electron microscopy, mitochondrial ATP, and NADH+/NADH levels were assessed in the CHEK2 knockout HCC cells with or without Metformin. Finally, cell-derived tumor xenograft was used to evaluate the role of CHEK2 knockout in vivo. We initially identified a potential drug target, CHEK2, through GWAS data analysis. Furthermore, we observed a significant upregulation of CHEK2 expression in HCC, which was found to be correlated with a poor prognosis. Subsequently, the results indicated that knocking out CHEK2 selectively affects the proliferation, cell cycle, senescence, and apoptosis of TP53-mutant HCC cells. Additionally, the introduction of Nultin-3 further intensified the functional impact on TP53-mutant cells. Then ClusterProfiler results showed high CHEK2 and TP53 mutation group was positively enriched in the mitochondrial ATP pathway. Then we used MitoSox, electron microscopy, mitochondrial ATP, and NADH + /NADH assay and found knockout of CHECK could induce the ATP pathway to inhibit the growth of HCC. Our research introduces a novel drug target for TP53-mutant HCC cells via mitochondrial ATP, addressing the limitation of Nultin-3 as a standalone treatment that does not induce tumor cell death.